Key result
Elevated hsTnT in non-STEACS patients predicts ~229% greater adverse event risk at 12 months.
Why the study?
The prognostic implications of serum hsTnT and copeptin levels in non-STEACS patients without raised standard TnT were uncertain, as was the role of copeptin beyond the first hours from admission.
Do hsTnT and copeptin levels predict adverse endpoints in non-STEACS patients without raised standard TnT?
Cohort (n=198)
Do hsTnT and copeptin levels predict adverse endpoints in non-STEACS patients without raised standard TnT?
Hazard Ratio: 3.29 (95% CI 1.33–7.49)
p-value: p=0.010
Elevated hsTnT, but not copeptin, predicts adverse events at 12 months in non-STEACS patients with negative standard TnT, suggesting its utility in guiding invasive management.
No takes yet. Share an insight, caveat, or question.
Elevated hsTnT may identify higher-risk non-STEACS patients with negative standard troponin; leaves open whether it should guide invasive management.
Hernández‐Romero et al. (2012) conducted a cohort in non-ST acute coronary syndromes (non-STEACS) (n=198). Raised high-sensitivity TnT (hsTnT) vs. Normal hsTnT levels / Controls was evaluated on adverse endpoints (HR 3.29, 95% CI 1.33-7.49, p=0.010). Raised levels of hsTnT in non-STEACS patients were predictive of adverse events at 12 months (HR 3.29; 95% CI 1.33-7.49; P=0.010).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: